Cargando…
Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation
Autores principales: | Treis, Diana, Umapathy, Ganesh, Fransson, Susanne, Guan, Jikui, Mendoza-García, Patricia, Siaw, Joachim T., Wessman, Sandra, Gordon Murkes, Lena, Stenman, Jakob J. E., Djos, Anna, Elfman, Lotta H. M., Johnsen, John Inge, Hallberg, Bengt, Palmer, Ruth H., Martinsson, Tommy, Kogner, Per |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830523/ https://www.ncbi.nlm.nih.gov/pubmed/35085006 http://dx.doi.org/10.1200/PO.21.00271 |
Ejemplares similares
-
Multifocal Neuroblastoma and Central Hypoventilation in An Infant with Germline ALK F1174I Mutation
por: Djos, Anna, et al.
Publicado: (2022) -
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018) -
Targeting anaplastic lymphoma kinase in neuroblastoma
por: Umapathy, Ganesh, et al.
Publicado: (2019) -
Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent
por: Guan, Jikui, et al.
Publicado: (2016) -
Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene
por: Djos, Anna, et al.
Publicado: (2013)